1,522 reports of this reaction
4.6% of all OLAPARIB reports
#5 most reported adverse reaction
ANAEMIA is the #5 most commonly reported adverse reaction for OLAPARIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,522 FDA adverse event reports linking OLAPARIB to ANAEMIA. This represents approximately 4.6% of all 33,417 adverse event reports for this drug.
Patients taking OLAPARIB who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is moderately reported among OLAPARIB users, representing a notable but not dominant share of adverse events.
In addition to anaemia, the following adverse reactions have been reported for OLAPARIB:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 1,522 FDA reports for OLAPARIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 4.6% of all adverse event reports for OLAPARIB, making it a notable side effect.
If you experience anaemia while taking OLAPARIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.